@article{oai:repo.qst.go.jp:00045761,
 author = {Kumata, Katsushi and Takei, Makoto and Yui, Jyouji and Ogawa, Masanao and Hatori, Akiko and Suzuki, Kazutoshi and Zhang, Ming-Rong and 熊田 勝志 and 武井 誠 and 由井 譲二 and 小川 政直 and 羽鳥 晶子 and 鈴木 和年 and 張 明栄},
 issue = {2},
 journal = {Journal of Labelled Compounds & Radiopharmaceuticals},
 month = {Feb},
 note = {Recent studies revealed that thalidomide (1) has unique and broad pharmacological effects on multi-targets although the
application of 1 in therapy is still controversial. In this study, we synthesized nitrogen-13-labeled thalidomide ([13N]1) as a
potential positron emission tomography (PET) probe using no-carrier-added [13N]NH3 as a labeling agent. By use of an
automated system, [13N]1 was prepared by reacting N-phthaloylglutamic anhydride (2) with [13N]NH3, following by
cyclization with carbonyldiimidazole in a radiochemical yield of 56712% (based on [11N]NH3, corrected for decay) and
specific activity of 49724 GBq/mmol at the end of synthesis (EOS). At EOS, 570–780MBq (n=7) of [13N]1 was obtained at a
beam current of 15 mA after 15 min proton bombardment with a synthesis time of 14 min from the end of bombardment. Using a small animal PET scanner, preliminary biodistribution of [13N]1 in mice was examined},
 pages = {53--57},
 title = {Radiosynthesis of 13N-labeled thalidomide using no-carrier-added [13N]NH3},
 volume = {53},
 year = {2010}
}